The Effect of Dulaglutide (LY2189265) on the Pharmacokinetics and Pharmacodynamics of Single Dose Warfarin in Healthy Subjects.

Trial Profile

The Effect of Dulaglutide (LY2189265) on the Pharmacokinetics and Pharmacodynamics of Single Dose Warfarin in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Dulaglutide (Primary) ; Warfarin
  • Indications Thromboembolism; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 Mar 2017 Results of pooled analysis from four trials (NCT01458210, NCT01436201, NCT01432938, and NCT01250834) assessing the effect of dulaglutide on PK of digoxin, warfarin, atorvastatin and Ortho-Cyclen and PD of warfarin, published in the Clinical Pharmacokinetics
    • 17 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 19 Sep 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top